Learn
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Clinical research with psychedelics has provided promising positive results for various mental disorders (Andersen et al., 2020; Bahji et al., 2020; Dos Santos et al., 2018; Vargas et al., 2020). However, sample sizes...
How Do Researchers Measure a Psychedelic Trip? The Power of 5D-ASC
The acronym 5D-ASC refers to Five-Dimensional Altered States of Consciousness. This framework offers researchers a powerful tool for analyzing and quantifying subjective experiences encountered during psychedelic journeys. Through careful development and empirical testing, 5D-ASC has emerged.
FDA Grants Accelerated Approval for as a Breakthrough Treatment for Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) granted accelerated approval for Leqembi (lecanemab-irmb) as a groundbreaking treatment. This marks a pivotal moment in the ongoing battle against Alzheimer's, with Leqembi being the second medication approved for the disease designed to tackle its fundamental pathophysiology.
The Increasing Popularity of Psychedelic-Enhanced Meditation and Mindfulness
In recent years, there has been a rise in the interest and exploration of different methods for achieving greater mental health, wellness, introspection, exploration, healing and spiritual development. One emerging...
Sustained effects of single doses of classical psychedelics in humans
Knudsen, G.M. (2022) Abstract The serotonergic classical psychedelics include compounds that primarily activate the brain’s serotonin 2 A receptor (5-HT2AR), such as LSD, psilocybin, and DMT (ayahuasca). The acute effects of...
Response of cluster headache to psilocybin and LSD
The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition. Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks;...
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s...
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
Major depressive disorder (MDD) is a substantial public health concern, affecting more than 300 million individuals worldwide. Depression is the number one cause of disability, and the relative risk of...